Brief: Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
03/03/2025 21:54
March 3 (Reuters) - Adverum Biotechnologies Inc ADVM.O: ADVERUM BIOTECHNOLOGIES INITIATES ARTEMIS PHASE 3 STUDY EVALUATING IXO-VEC FOR WET AMD Source text: ID:nGNX835Yyx Further company coverage: ADVM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)